nach oben

Breast Cancer Research and Treatment

Erschienen in:

01.02.2020 | Review

Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis

verfasst von: Yan Li, Yidong Zhou, Feng Mao, Yan Lin, Xiaohui Zhang, Songjie Shen, Qiang Sun

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Triple-negative breast cancer (TNBC) pertains to a breast cancer subtype that has the highest metastatic and recurrence rates. The effectiveness of capecitabine as adjuvant chemotherapy for TNBC has remained unclear. This study conducted a meta-analysis of the efficacy of capecitabine as adjuvant chemotherapy for early-stage TNBC treated with taxane-/anthracycline-based chemotherapy.

Methods

We identified relevant research reports in online databases until May 2019. We finally included seven randomized clinical trials to perform this meta-analysis. Altogether, the seven trials enrolled 3151 early-stage TNBC patients, with 1552 receiving standard (neo)adjuvant chemotherapy regimens and 1599 receiving addition of capecitabine in the adjuvant settings besides standard regimens.

Results

A meta-analysis of the seven trials revealed a significant increase in disease-free survival (DFS) with the addition of capecitabine (Hazard ratio (HR) = 0.77, 95% CI 0.66–0.90). This improvement in DFS was significant both in trials conducted in America-Europe and in Asia. In trials involving six to eight cycles of capecitabine addition, we observed a significant improvement in DFS. Furthermore, in the meta-analysis of six trials, we detected a significant increase in overall survival (OS) favoring capecitabine (HR = 0.69, 95% CI 0.56–0.85).

Conclusions

Adjuvant addition of capecitabine to early-stage TNBC patients receiving standard chemotherapy showed significant DFS and OS improvement. Future studies involving the selection of patients that may have the highest survival benefit from adding capecitabine are warranted.

Nur mit Berechtigung zugänglich

Gadi VK, Davidson NE (2017) Practical approach to triple-negative breast cancer. J Oncol Pract 13(5):293–300. https://doi.org/10.1200/JOP.2017.022632 CrossRefPubMed

Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart M, Pritchard K (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379(9814):432–444. https://doi.org/10.1016/s0140-6736(11)61625-5 CrossRefPubMed

Ali AM, Ansari JAK, El-Aziz NMA, Abozeed WN, Warith AMA, Alsaleh K, Nabholtz JM (2017) Triple negative breast cancer: a tale of two decades. Anticancer Agents Med Chem 17(4):491–499. https://doi.org/10.2174/1871520616666160725112335 CrossRefPubMed

Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzen F, Noh SH, for the CLASSIC trial investigators (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379(9813):315–321. https://doi.org/10.1016/S0140-6736(11)61873-4 CrossRefPubMed

Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, Kim HH, Choi JH, Kim HK, Yu W, Lee JI, Shin DB, Ji J, Chen JS, Lim Y, Ha S, Bang YJ, investigators Ct (2014) Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 15(12):1389–1396. https://doi.org/10.1016/S1470-2045(14)70473-5 CrossRefPubMed

Pallis AG, Boukovinas I, Ardavanis A, Varthalitis I, Malamos N, Georgoulias V, Mavroudis D (2012) A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. Ann Oncol 23(5):1164–1169. https://doi.org/10.1093/annonc/mdr405 CrossRefPubMed

Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733–2743. https://doi.org/10.1056/NEJMoa064320 CrossRefPubMed

Miles D, von Minckwitz G, Seidman AD (2002) Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist 7(Suppl 6):13–19PubMed

Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17(2):485–493. https://doi.org/10.1200/JCO.1999.17.2.485 CrossRefPubMed

10.

Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R, Ahlgren J, Auvinen P, Lahdenpera O, Kosonen S, Villman K, Nyandoto P, Nilsson G, Poikonen-Saksela P, Kataja V, Junnila J, Bono P, Lindman H (2017) Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. JAMA Oncol 3(6):793–800. https://doi.org/10.1001/jamaoncol.2016.6120 CrossRefPubMedPubMedCentral

11.

Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R, Ahlgren J, Auvinen P, Paija O, Helle L, Villman K, Nyandoto P, Nilsson G, Pajunen M, Asola R, Poikonen P, Leinonen M, Kataja V, Bono P, Lindman H (2012) Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. J Clin Oncol 30(1):11–18. https://doi.org/10.1200/jco.2011.35.4639 CrossRefPubMed

12.

Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R, Ahlgren J, Auvinen P, Saarni O, Helle L, Villman K, Nyandoto P, Nilsson G, Leinonen M, Kataja V, Bono P, Lindman H (2014) Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland capecitabine trial (FinXX). Acta Oncol 53(2):186–194. https://doi.org/10.3109/0284186x.2013.820840 CrossRefPubMed

13.

O'Shaughnessy J, Koeppen H, Xiao Y, Lackner MR, Paul D, Stokoe C, Pippen J Jr, Krekow L, Holmes FA, Vukelja S, Lindquist D, Sedlacek S, Rivera R, Brooks R, McIntyre K, Brownstein C, Hoersch S, Blum JL, Jones S (2015) Patients with slowly proliferative early breast cancer have low five-year recurrence rates in a phase III adjuvant trial of capecitabine. Clin Cancer Res 21(19):4305–4311. https://doi.org/10.1158/1078-0432.ccr-15-0636 CrossRefPubMed

14.

Martín M, Barrios CH, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J, Ruiz A, García-Sáenz JA, Torres R, de la Haba J, García E (2018) Efficacy results from CIBOMA/2004-01_GEICAM/2003-11 study: a randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer. https://www.abstracts2view.com/sabcs/view.php?nu=SABCS18L_864&terms=. Accessed 26 Apr 2019

15.

Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H, Jeong J, Kim A, Park KH, Sasano H, Ohashi Y, Toi M (2017) Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 376(22):2147–2159. https://doi.org/10.1056/NEJMoa1612645 CrossRefPubMed

16.

Zhang ZC, Xu QN, Lin SL, Li XY (2016) Capecitabine in combination with standard (neo)adjuvant regimens in early breast cancer: survival outcome from a meta-analysis of randomized controlled trials. PLoS ONE 11(10):e0164663. https://doi.org/10.1371/journal.pone.0164663 CrossRefPubMedPubMedCentral

17.

Chen G, Guo Z, Liu M, Yao G, Dong J, Guo J, Ye C (2017) Clinical value of capecitabine-based combination adjuvant chemotherapy in early breast cancer: a meta-analysis of randomized controlled trials. Oncol Res 25(9):1567–1578. https://doi.org/10.3727/096504017X14897173032733 CrossRefPubMedPubMedCentral

18.

Natori A, Ethier JL, Amir E, Cescon DW (2017) Capecitabine in early breast cancer: a meta-analysis of randomised controlled trials. Eur J Cancer 77:40–47. https://doi.org/10.1016/j.ejca.2017.02.024 CrossRefPubMed

19.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700. https://doi.org/10.1136/bmj.b2700 CrossRefPubMedPubMedCentral

20.

Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP (1998) Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352(9128):609–613. https://doi.org/10.1016/s0140-6736(98)01085-x CrossRefPubMed

21.

Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1–12CrossRefPubMed

22.

Zhang X, Zhou Y, Mao F, Lin Y, Guan J, Sun Q (2015) Efficacy and safety of pirarubicin plus capecitabine versus pirarubicin plus cyclophosphamide in Chinese node-negative breast cancer patients: a 4-year open-label, randomized, controlled study. Med Oncol 32(10):240. https://doi.org/10.1007/s12032-015-0686-8 CrossRefPubMed

23.

Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16. https://doi.org/10.1186/1745-6215-8-16 CrossRefPubMedPubMedCentral

24.

Zhimin S, Li J, Pang D, Wang C, Jiang J, Yang S, Liu Y, Fu PF, Sheng Y, Zhang G, Cao L (2016) Cbcsg-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer (2012–2016). 2016 ASCO Annual Meeting|Virtual Meeting|Meeting Library. China Breast Cancer Clinical Study Group. https://meetinglibrary.asco.org/content/123895?media=vm.html. Accessed 26 Apr 2019

25.

Martin M, Ruiz Simon A, Ruiz Borrego M, Ribelles N, Rodriguez-Lescure A, Munoz-Mateu M, Gonzalez S, Margeli Vila M, Barnadas A, Ramos M, Del Barco BS, Jara C, Calvo L, Martinez-Janez N, Mendiola Fernandez C, Rodriguez CA, Martinez de Duenas E, Andres R, Plazaola A, de la Haba-Rodriguez J, Lopez-Vega JM, Adrover E, Ballesteros AI, Santaballa A, Sanchez-Rovira P, Baena-Canada JM, Casas M, del Carmen CM, Carrasco EM, Lluch A (2015) Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: results from the GEICAM/2003-10 Study. J Clin Oncol 33(32):3788–3795. https://doi.org/10.1200/JCO.2015.61.9510 CrossRefPubMed

26.

Furlanetto J, Eiermann W, Marme F, Reimer T, Reinisch M, Schmatloch S, Stickeler E, Thomssen C, Untch M, Denkert C, von Minckwitz G, Lederer B, Nekljudova V, Weber K, Loibl S, Mobus V (2016) Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN Study. Ann Oncol 27(11):2053–2059. https://doi.org/10.1093/annonc/mdw315 CrossRefPubMed

27.

Kelly CM, Green MC, Broglio K, Thomas ES, Brewster AM, Valero V, Ibrahim NK, Gonzalez-Angulo AM, Booser DJ, Walters RS, Hunt KK, Hortobagyi GN, Buzdar AU (2012) Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. J Clin Oncol 30(9):930–935. https://doi.org/10.1200/jco.2011.36.2079 CrossRefPubMed

28.

Mobus V, von Minckwitz G, Jackisch C, Luck HJ, Schneeweiss A, Tesch H, Elling D, Harbeck N, Conrad B, Fehm T, Huober J, Muller V, Bauerfeind I, du Bois A, Loibl S, Nekljudova V, Untch M, Thomssen C (2017) German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients. Ann Oncol 28(8):1803–1810. https://doi.org/10.1093/annonc/mdx203 CrossRefPubMed

29.

von Minckwitz G, Conrad B, Reimer T, Decker T, Eidtmann H, Eiermann W, Hackmann J, Mobus V, Marme F, Potenberg J, Stickeler E, Simon E, Thomssen C, Huober J, Denkert C, Alfer J, Jackisch C, Nekljudova V, Burchardi N, Loibl S (2015) A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52). Cancer 121(20):3639–3648. https://doi.org/10.1002/cncr.29506 CrossRef

30.

Chumsri S Asleh K, Brauer HA, Mashadi-Hossein A, Lauttia LS, Lindman H, Nielsen TO, Joensuu H, Thompson EA (2018) Predictive gene signatures of adjuvant capecitabine benefit in triple negative breast cancer in the FinXX trial (Mayo Clinic, Jacksonville, FL). https://www.abstracts2view.com/sabcs18/view.php?nu=SABCS18L_800.

Titel: Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis
verfasst von: Yan Li
Yidong Zhou
Feng Mao
Yan Lin
Xiaohui Zhang
Songjie Shen
Qiang Sun
Publikationsdatum: 01.02.2020
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 3/2020
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-019-05513-4

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Breast density measured volumetrically in a clinical environment: cross-sectional study with photon counting technology

Axillary lymph node dissection in node-positive breast cancer: are ten nodes adequate and when is enough, enough?

Evaluation of the anti-Thomsen–Friedenreich antibodies Nemod-TF1 and Nemod-TF2 as prognostic markers in breast cancer

The prognostic value of NRF2 in breast cancer patients: a systematic review with meta-analysis

Exome sequencing study of Russian breast cancer patients suggests a predisposing role for USP39

Results of a phase I, non-randomized study evaluating a Magnetic Occult Lesion Localization Instrument (MOLLI) for excision of non-palpable breast lesions

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie